Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Primary Inclusion Criteria:

Relapsed or refractory histologically or cytologically confirmed Stage IIIB, IV, or recurrent NSCLC
Previously treated and failed to respond to standard therapy or progressed after standard therapy
18 years of age or older

Primary Exclusion Criteria:

Received a non-FDA approved investigational agent within the last 4 weeks.
Previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized monoclonal antibodies
Infection requiring antibiotics or hospitalization within the last 2 weeks
HIV, Hepatitis-B, Hepatitis-C
Pregnant or breast-feeding women
Major surgery within the last 4 weeks
History of other cancers within the past 5 years